Home Capabilities Localisation

Localisation

Building a Sustainable Pharmaceutical Future

Building Sustainable Pharmaceutical Future

Sudair Pharma was established with a clear objective:

To localise the manufacturing of advanced pharmaceutical products in Saudi Arabia and contribute to a resilient healthcare ecosystem.

Localisation Overview

Sudair Pharma was established with a clear objective: To localise the manufacturing of advanced pharmaceutical products in Saudi Arabia and contribute to a resilient healthcare ecosystem.

 

By combining international expertise with local manufacturing capabilities, Sudair Pharma is accelerating pharmaceutical localisation while supporting national healthcare priorities, patient access, and economic development.

  • Supporting Saudi Vision 2030

  • Reducing Dependence on Imported Medicines

  • Expanding High-Technology Production

  • Strengthening National Drug Security

  • Advancing Local Pharmaceutical Manufacturing

  • Developing National Scientific Capabilities

  • Localization of 41 Products

Supporting Saudi Vision 2030

Contributing to a National Transformation

Sudair Pharma’s localisation initiatives directly support Saudi Vision 2030 and the National Biotechnology Strategy by expanding local manufacturing capabilities, increasing pharmaceutical self-sufficiency, strengthening healthcare resilience, and encouraging innovation across the life sciences sector.

Strategic Contributions

01

Pharmaceutical Localisation

02

Healthcare Sustainability

03

National Drug Security

04

Biotechnology Development

05

Economic Diversification

06

Knowledge Transfer

Localising High-Value Pharmaceutical Manufacturing

Sudair Pharma is investing in specialized manufacturing facilities that support the localisation of complex pharmaceutical products while meeting international quality standards. 

Oncology Manufacture تصنيع أدوية الأورام
01

High Potent Manufacturing

Saudi Arabia’s first specialized anti-neoplastic manufacturing facility, producing advanced anti-neoplastic and hematology medicines.

Respiratory Manufacture تصنيع مستحضرات علاج أمراض الجهاز التنفسي
02

General Formulation (GF) Site

Constructed 2022  Manufacturing since 2023
Manufactures and packs general-formulary tablets and capsules, extending our range of locally produced medicines beyond high-potent products.

Insulin Manufacture تصنيع الإنسولين
03

Insulin Manufacturing

Developing a comprehensive insulin manufacturing facility, progressing from secondary packaging toward full formulation, filling, and commercial production.

Biosimilars & Monoclonal Antibodies المستحضرات الحيوية المماثلة والأجسام المضادة وحيدة النسيلة
04

Biosimilars & Monoclonal Antibodies

Building advanced biologics manufacturing capabilities for anti-neoplastic, immunology, and chronic diseases.

A multi-pillar approach

Localisation at Sudair Pharma extends beyond manufacturing. It is a comprehensive strategy built around innovation, partnerships, scientific development, and advanced production technologies.

  • Pillar 01

    Advanced Manufacturing

    Developing specialized pharmaceutical manufacturing capabilities for anti-neoplastic, biologics, insulin, respiratory therapies, and other high-value medicines.

  • Pillar 02

    Technology Transfer

    Working with international pharmaceutical partners to transfer manufacturing knowledge, technical expertise, and production technologies into Saudi Arabia.

  • Pillar 03

    Scientific Collaboration

    Building partnerships with universities, research institutions, and healthcare organizations to strengthen pharmaceutical innovation and workforce development.

  • Pillar 04

    National Capability Development

    Investing in local talent, infrastructure, and advanced manufacturing technologies to build long-term pharmaceutical self-sufficiency.

14

 

Riyadh skyline with the Saudi flag, with the NUPCO and Sanofi partner logos.

Partnerships

Strategic Partnerships Supporting Localisation

Collaborating to Strengthen National Healthcare

Sudair Pharma works with global pharmaceutical companies, government entities, healthcare organizations, and academic institutions to accelerate localisation initiatives.

National Capability, Built to Last

Reducing dependence on imported medicines through advanced local manufacturing.